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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) after
myeloablative chemoradiotherapy is an effective therapy for
a variety of disorders of hematopoiesis including hematologic
malignancies [1]. Thrombocytopenia is a significant compli-
cation that must be effectively managed after HSCT to pre-
vent severe bleeding. Thrombocytopenia occurring after
HSCT may be isolated and prolonged [2-4]. Variables asso-
ciated with the rate of re c o v e ry of platelet counts after both
autologous and allogeneic HSCT include: (1) source of stem
c e l l s , (2) CD34+ cell count, (3) platelet count before autolo-
gous HSCT, (4) graft-versus-host disease (GVHD), (5)
infection, (6) veno-occlusive disease (VOD); and (7) the type
of hematopoietic or malignant disease present at transplant
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ABSTRACT
Delayed platelet re c o v e ry is a significant complication after both autologous and allogeneic hematopoietic stem cell
transplantation (HSCT). A multicenter, phase I dose-escalation study of recombinant human thro m b o p o i e t i n
( rhTPO) was conducted to assess its safety and to obtain pre l i m i n a ry data on its efficacy in patients with persistent
s e v e re thrombocytopenia (<2 0 , 0 0 0 /µL) >35 days after HSCT. Thirty-eight patients, 37 of whom were evaluable, were
e n rolled in the study from April 1996 through January 1997. rhTPO was administered at doses of 0.6, 1.2, and 2.4
µg/kg as a single dose (group A) or in multiple doses every 3 days for a total of 5 doses (group B). No signific a n t
adverse effects were observed. Ten patients had re c o v e ry of platelet counts during the 28-day study period; 3 of these
10 had an increase in marrow megakaryocyte content 7 days after completing treatment with rhTPO. When all base-
line marrows were compared with samples after rhTPO treatment, there was no diff e rence in marrow megakary o c y t e
content (P = 0.49). This study design could not answer the question of whether the recoveries of platelet counts
o b s e rved in some patients were spontaneous or influenced by rhTPO treatment; nonetheless, the authors found no
c o rrelation between the dose of rhTPO and the re c o v e ry of platelet counts. Increases in serum TPO levels were
dose-dependent and remained significantly elevated for up to 72 hours after treatment. To evaluate response, furt h e r
studies of treatment strategies with rhTPO in patients with delayed platelet re c o v e ry are re q u i re d .
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[2,4]. Median times to re c o v e ry of platelet counts after
t r a n s p l a ntation with autologous marro w, peripheral blood
stem cells (PBSC), and allogeneic marrow and PBSC were
40, 13, 27, and 16 days, respectively [2]. At 8 weeks after
transplantation, 20% and 24% of autologous and allogeneic
m a rrow recipients and 5% and 19% of autologous and allo-
geneic PBSC recipients, re s p e c t i v e l y, were still platelet trans-
fusion–dependent. After an initial re c o v e ry of platelet counts,
a second decrease to <2 0 , 0 0 0 /µL may occur in 5% to 28% of
patients [4]. Effective strategies to increase platelet counts in
t h rombocytopenic patients after transplantation may re d u c e
bleeding complications and decrease the need for platelet
t r a n s f u s i o n s .
Thrombopoietin is the ligand for c-mpl and is the key
cytokine regulating megakaryocytopoiesis [5-11]. It is
l a rgely produced in the liver, but by other organs as well
[12,13]. After binding to c-mpl, which is expressed on
platelets and megakaryocytes, thrombopoietin is intern a l-
ized and metabolized, resulting in the elimination of the
cytokine [14]. Thrombopoietin serum levels are re g u l a t e d
by platelet and megakaryocyte mass [15]. After HSCT,
s e rum thrombopoietin levels inversely correlate with
platelet count [16,17]. In animal models of myelosuppre s-
sion, the administration of recombinant thro m b o p o i e t i n
reduces severity and duration of thrombocytopenia [18-26].
After administration of recombinant human thrombopoietin
( rhTPO) to patients with advanced cancer, before chemo-
therapy treatment, both platelet counts and megakaryocyte
m a rrow content increase substantially [27,28]. Administer-
ing rhTPO to patients after chemotherapy has also resulted
in a higher nadir and a shorter time to recovery of platelet
count [29,30]. Based on the demonstration of safety and effi-
cacy in preclinical and early clinical studies, a phase I study
was conducted to evaluate the safety and tolerance level of
rhTPO as treatment for delayed platelet recovery in patients
after HSCT. Secondary objectives included evaluating its
efficacy and obtaining pharmacokinetic data.
MATERIALS AND METHODS
Pa t i e n t s
F rom April 1996 through January 1997, 38 patients
w e re enrolled in this study, which involved 9 institutions
within the United States. After autologous or allogeneic
H S C T, patients ≥16 years of age were eligible for the
study if platelet re c o v e ry had not occurred by day 35 or, if
after initial platelet re c o v e ry, there was a failure to main-
tain a platelet count ≥2 0 , 0 0 0 /µL without a platelet trans-
fusion for 7 or more days before the start of tre a t m e n t .
Platelet re c o v e ry after transplantation was defined as the
maintenance of a platelet count ≥2 0 , 0 0 0 /µL without a
platelet transfusion for at least 7 days. The study was
a p p roved by the institutional review board at each center
and explained in detail to each patient, who in turn pro-
vided written informed consent.
Patients were not eligible for therapy if they had any of
the following: (1) inadequate renal function (cre a t i n i n e
>2.0 mg/dL) or hepatic function (bilirubin >1.5 mg/dL;
1.5-2.5 mg/dL was allowed if serum glutamic-oxalocetic
transaminase (SGOT) and serum glutamic-pyru v i c
transaminase (SGPT) values were <2.5 times normal and
the prothombin time was within normal limits); (2) pre v i-
ous history of platelet disorder or bleeding diathesis; (3)
h i s t o ry of any clinically significant thromboembolic event
(excluding clotting of a central line); (4) active VOD, or a
h i s t o ry of clinically significant VOD (defined as biliru b i n
≥6.0 mg/dL with painful hepatomegaly after transplanta-
tion); (5) evidence of pro g ressive neoplastic disease; (6)
serious bleeding requiring >2 units of packed red blood
cells or causing a ≥10% decrease in hematocrit in 1 day
within 7 days of enrolling in the study; (7) uncontro l l e d
serious active infection within the previous 7 days; (8) any
experimental drug use within 28 days of the study; (9) pro-
g ressive GVHD; or (10) re c o rded temperature >3 8 . 5 ° C
( 1 0 1oF) within 72 hours of the start of the study. Other
hematopoietic growth factors, aside from granulocyte
colony-stimulating factor (G-CSF), were not allowed during
any of the treatment cycles of this study. Platelet transfu-
sions were administered as clinically indicated for bleeding.
P rophylactic platelet transfusions were not administere d
routinely for platelet counts ≥2 0 , 0 0 0 /µL. Routine platelet
transfusions, if re q u i red, were administered after the morn-
ing platelet count and pharmacokinetic studies. A platelet
transfusion event was defined as a pool of 6 units of ran-
dom-donor platelets pre p a red from donated whole blood
units or single-donor plate lets collected by platelet
p h e re s i s.
Study Design
The study was a multicenter phase I nonrandomized
open-label dose-escalation trial of single (group A) or multi-
ple (group B) intravenous doses of rhTPO administered to
patients who had delayed platelet re c o v e ry after either autol-
ogous or allogeneic HSCT. The trial was designed to include
6 patients in each of 6 dose groups. Two additional patients
w e re included in group A at the dose level of 0.6 µg / k g .
Because 1 patient had died on day 13 of the study and to
maintain study numbers, another patient joined group A.
The second patient was enrolled because of simultaneous
registration from 2 clinical sites for the last available slot in
the cohort. The last patient slot of group A at the dose level
of 2.4 µg/kg was not filled, but that patient was instead
e n rolled in group B at the dose level of 0.6 µg/kg. Patients
w e re stratified at each dose group according to the type of
transplant pro c e d u re undergone so that at least 1 patient at
each dose level had received an allogeneic transplant and 1
had received an autologous transplant.
Dose levels were assigned in ascending order at 0.6, 1.2,
and 2.4 µg/kg based on actual body weight. Patients in
group A at all dose levels received rhTPO as a single intra-
venous injection on the first day (day 0) of the study period.
Patients in group B received rhTPO every 3 days for a total
of 5 intravenous injections. The study period consisted of
the 28 days following the initial rhTPO administration.
Patients could be off e red additional treatment with
rhTPO during an optional extension period (OEP) if, after
the study period, patients had not re c o v e red acceptable
platelet counts. The OEP was an additional 28-day cycle
after the study period during which the patient could receive
rhTPO at the same dose and frequency as during the study
or at the highest dose that had been safely tolerated to that
point in the trial. To be eligible for the OEP, patients must
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have safely tolerated rhTPO administration during the orig-
inal 28-day study period, satisfied all eligibility criteria for
e n t ry into the study, had negative tests for neutralizing
TPO-specific antibodies, and been free of all evidence of
dose-limiting toxicity. 
After treatment with rhTPO, re c o v e ry of platelets was
defined as the ability to achieve and maintain a platelet
count ≥20,000/µL without a platelet transfusion for at least
7 consecutive days within the 28-day study period. A sec-
o n d a ry endpoint was re c o v e ry  of plate let counts to
≥5 0 , 0 0 0 /µL, maintained without platelet transfusion for
7 days.
Appropriate to the trial design and objectives, the analy-
ses were descriptive in nature.
D o s e , Route, and Regimen of rhTPO
rhTPO (Genentech, San Francisco, CA) is a polypep-
tide derived from a genetically engineered mammalian
cell line containing the human gene for thro m b o p o i e t i n .
It was provided as a sterile liquid ready for pare n t e r a l
administration in a pre s e rv a t i v e - f ree buffer solution.
rhTPO was shipped on wet ice and stored at tempera-
t u res of 2-8°C (35-46°F). Endotoxin levels were less than
0.4E U/mL according to limulus amebocyte lysate clot
f o rmation assay.
Study Assessments
All screening evaluations were performed before initial
administration of the study drug and consisted of a medical
history and physical examination, chest X-ray, electrocardio-
gram, complete blood count (CBC) with diff e rential and
platelet count, serum chemistry, electrolyte profile, urinaly-
sis, serologic studies (to detect TPO-specific antibodies),
and a bone marrow biopsy and aspirate. The serum chem-
i s t ry and electrolyte profile included sodium, potassium,
chloride, bicarbonate, total bilirubin, alkaline phosphatase,
SGPT, SGOT, blood urea nitrogen (BUN), creatinine, cal-
cium, phosphorous, uric acid, lactate dehydrogenase, and
total protein.
During the 28-day study period, a weekly interim his-
t o ry and a symptom-directed physical examination were
u n d e rtaken for each patient. CBC and diff e rential with
platelet count was completed during the first 5 days of treat-
ment and then at least twice weekly or as clinically indi-
cated. Weekly serum chemistry, electrolyte profiles, and
assays for TPO-specific antibodies were also re c o rd e d .
Patients were also subject to a urinalysis 28 days after the
first rhTPO infusion and a bone marrow biopsy and aspirate
7 days after the final rhTPO administration. Evaluations
during the OEP followed the same schedule as that during
the original study period. After completing the 28-day study
period or the OEP, patients were followed for an additional
28 days to assess continuing or new adverse events. Patients
w e re evaluated every 2 weeks (days 14 and 28) during this
follow-up period.
M a r row Assessment
Bone marrow aspirates and biopsies were acquire d
b e f o re and 1 week after rhTPO treatment. All marro w
samples were assessed by the clinical pathologist at the site
w h e re the patient had undergone transplantation. Thre e
levels of megakayocyte marrow content were established
based on the clinical re p o rts: absent, decreased, or norm a l .
In addition, the marrow samples collected for the study
w e re evaluated by an independent study pathologist. To
describe the observations of the pathologist, megakay-
ocytes were quantitated. Because of the limitation of the
samples submitted, however, the assessment was only
semiquantitative in some samples. The quantitation of
m e g a k a ryocytes was based solely on tissue sections made
f rom either marrow biopsies or particle preparations. All
slides were given numerical codes to mask the source and
date of each specimen. Megakaryocytes were quantitated
by counting the total number in the section and dividing
by the total number of optical fields counted. Biopsies
w e re counted with 103 optical fields, and particles with
1 63 optical fields. Identification of a megakaryocyte in
question was resolved by using higher- p o w e red instru-
ments. The field diameter of the 103 was 1.8 mm and
that of the 163 was 1.12 mm, using a Leitz Laborlux
(E. Leitz, Stuttgart, Germany) with 103 eyepieces and an
18° field of view. The biopsies varied somewhat in width,
most filling 70% to 90% of the total field. No attempt was
made to adjust for these slight diff e rences in the width of
various biopsies. Determinations of the megakaryocytes in
p a rticle sections were more semiquantitative, because the
sections did not contain contiguous marrow particles. The
m i c roscopist visually grouped contiguous clusters until
they approximated the volume of the 163 field. To assess
the effect of treatment, the results of baseline marro w s
w e re pooled and compared with marrow samples collected
after treatment with rhTPO re g a rdless of dose.
T h r ombopoietin Assay
S e rum samples were collected 5 minutes before and
10 minutes after each rhTPO administration and 24 hours
after the final rhTPO administration. Samples were
f rozen at –70°C for shipping to a central laboratory
(Genentech) . S e rum concentrations of  rhTPO were
d e t e rmined using a c-mpl–based enzyme-l inked
immunosorbent assay (ELISA) with a detection limit of
0.078 ng/mL [17,31].
T h r ombopoietin Antibody Assay 
S c reening for antibodies to TPO was perf o rmed on
s e rum samples drawn twice before start of the study and
weekly during the study. Sera were rigorously scre e n e d
using ELISA assays based on full-length and tru n c a t e d
TPO; sera that were reactive in the screen were tested in a
functional assay based on blocking c-mpl receptor binding
and a bioassay based on the inhibition of a TPO-dependent
cell line [32]. Neutralizing antibodies were defined as being
i n h i b i t o ry in the bioassay and associated with clinically
s i g n i ficant thro m b o c y t o p e n i a .
RESULTS
Patients and Tr e a t m e n t s
Demographics and transplant characteristics of the
38 patients enrolled in the study are summarized in Table 1.
T h i rt y - t h ree of the 38 patients failed to recover platelet
counts ≥2 0 , 0 0 0 /µL at any time after transplantation. Five
28
patients who had undergone allogeneic transplantation ini-
tially achieved a re c o v e ry of platelet counts ≥50,000 and
w e re independent of platelet transfusions but then experi-
enced a subsequent sustained decrease in platelet counts to
<2 0 , 0 0 0 /µL and became platelet transfusion–dependent
( s e c o n d a ry failure of platelet re c o v e ry ) .
T h i rty-six of the 38 patients completed the initial
28-day study after start of treatment; during the study,
1 patient died and a second elected to discontinue part i c i-
pation. Thirt y - t h ree of these 36 completed the follow-up
period; 1 patient died before completion of the follow-up
period and 2 patients elected to withdraw. Eleven patients
had repeat rhTPO treatments in the OEP: 8 patients had
only 1 OEP treatment, 2 had 2, and 1 had 5.
A d v erse Ev e n t s
Sixteen patients experienced serious adverse events.
Overall, no pattern of adverse events was associated with
the administration of rhTPO. The adverse events re c o rd e d
w e re consistent with those seen in an immunosuppre s s e d
transplant patient population with thrombocytopenia and,
in some cases, neutropenia (Table 2). Other adverse events
that were possibly related to rhTPO administration were
less serious and are listed in Table 3. No thro m b o t i c
episodes occurred during the observation period. Tw e n t y -
two bleeding events were re p o rted during the study period,
but were of limited clinical significance. With the exception
of 1 pat ient with gastrointestinal  hemorrhage, none
re q u i red support with red blood cell transfusions (Table 4). 
Two patients died while participating in the study, 1
during the study period and the second during follow-up.
A third patient’s death was re p o rted after the follow-up
period. All 3 deaths were considered to be secondary to
complications related to the transplant and included
parainfluenza virus pneumonia, disseminated Asperg i l l u s ,
and Aspergillus pneumonia/central nervous system
infection. 
No significant trends in the occurrence, extent, or dis-
tribution of abnormal values were observed for seru m
S G O T, SGPT, total bilirubin, creatinine, BUN, or other
s e rum chemistries. There were no changes in urinalysis
findings. Hematologic toxicity related to the administra-
tion of rhTPO was not observ e d .
Platelet Recov e r y 
A total of 10 patients achieved a plate let count
≥2 0 , 0 0 0 /µL and were independent of platelet transfusions
during the 28-day study period (Table 5). Median platelet
Table 1. Patient Characteristics (n=38)*
Male/female 25/13
Median age (range) 48.1 y (18.6-68.2)
ECOG performance status 0/1/2 5/27/6
Median days since transplant (range) 64.5 (40-129)
Diagnoses
Leukemia 16
Acute myeloid leukemia 8
Chronic myelogenous leukemia 5
Acute lymphocytic leukemia 2
Acute undifferentiated leukemia 1
Non-Hodgkin’s lymphoma 11
Myelodysplastic syndrome 5
Breast cancer 4
Hodgkin’s disease 1
Aplastic anemia 1
Stem cell source
Allogeneic marrow
Matched unrelated 12
Matched related 4
Mismatched related 1
Allogeneic PBSC
Matched related 5
Autologous PBSC 11
Autologous PBSC 1 marrow 3
Autologous marrow 2
Patient history at baseline
Graft-versus-host disease 11
Cytomegalovirus status
Active viremia 5
History of infection 3
Veno-occlusive disease 3
Absolute neutrophil count (day 0)
≤500/mL 4
≤1500/mL 7
*ECOG indicates Eastern Cooperative Oncology Group; PBSC, peripheral blood
stem cells.
Table 2. Adverse Events During Observation Periods of the Study
Event Number of Patients
Infection/sepsis 23
Bacterial sepsis 5
Viral infection 10
Fungal infection 4
Bacterial pneumonia 4
Fever 10
Graft-versus-host disease 7
Disease relapse 3
Table 3. rhTPO-related Adverse Events During the Study Period
Event Number of Patients
Headache 3
Arthralgia 1
Bone pain 1
Epistaxis 1
Fatigue 1
Fever 1
Lightheadedness 1
Petechiae 1
TPO-specific antibodies* 0
*Antibody detected in one patient during pretreatment screening evaluation.
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count at the end of the 28-day cycle in patients with
platelet re c o v e ry was 28,000/µL. (range 25,000-134,000).
Platelet counts showed a gradual sustained incre a s e
t h rough the 28-day period in all re c o v e red patients. No
responding patient experienced a decline in platelet counts
during follow-up relative to those observed at the end of
the 28 days. Three of the 10 patients with platelet re c o v e ry
w e re classified as having secondary failure of platelet
re c o v e ry at study entry. Only 2 of the 10 patients exhibited
a re c o v e ry to >5 0 , 0 0 0 /µL. The platelet recoveries occurre d
without association to rhTPO dose level. No d o s e – re s p o n s e
e ffect was observed between TPO and the frequency of
either platelet or red blood cell transfusion events dur-
ing the study (Table 6). Of the 11 patients enrolled in
the OEP, all but 1 had the additional treatments at the
same rhTPO dose that had been received during the
original study. One patient who entered into 5 sequen-
tial OEPs had an escalated dose of rhTPO as the study
p ro g ressed. In total, 2 patients had re c o v e ry of platelet
counts during these additional rhTPO treatments. In 1
pat ie nt  the re w as  re c o v e ry  of  p late let  count s  to
3 1 , 0 0 0 /µL by day 29 of the first OEP; in the second
pat ie nt  the re was  re c o v e ry  of  p lat elet  c ounts  to
5 0 , 0 0 0 /µL by day 28 of a second OEP.
Assessment of Marrow Megakaryocyte Content
Of the 37 patients evaluable on the study, 32 had base-
line marrow samples of sufficient quantity and quality and
w e re evaluated semiquantitatively for megakaryocyte content
by pathologists at the study site. Eight had absent, 22 ha d
d e c reased, and 2 had normal megakaryocyte content.
Twenty-seven patients had adequate marrow samples 1 w e e k
after rhTPO treatment for comparison with the baseline
sample. Six patients increased by 1 level of megakary o c y t e
m a rrow content from their baseline evaluation. Only 2 of
these 6 patients also had evidence of clinical impro v e m e n t
with the re c o v e ry of platelet counts by day 28.
Slides from the marrow samples taken from 36 patients
w e re available for assessment by the independent study
pathologist. According to independent analyses, 3 had nor-
mocellular marrows (>70% cellularity) and all but 1 had a
d e c rease in megakaryocyte content before transplantation.
An association between an increase in megakaryocyte con-
tent and rhTPO dose was not observed. The mean number
of megakaryocytes per microscopic field in the pooled
baseline marrow samples was 0.95 ± 1.18 compared with
1.54 ± 2.24 after rhTPO treatment (P = 0.49, Wi l c o x o n ’s
rank-sum). Three patients had an increase in megakary o-
cyte content associated with re c o v e ry of platelet counts
( Table 5).
rhTPO Pharmacokinetics
In the presence of a normal marrow and platelet
count, TPO levels are usually <0.078 ng/mL, the limit of
detection for the assay used in this study (Y.G. Meng,
unpublished observations and Meng et al. [17]). All
patients in this study had elevated TPO levels before
receiving the first dose of rhTPO. The mean baseline
TPO level for evaluable patients was 1.38 ng/mL (SD ±
1.17). There was a dose–response increase in the peak
s e rum TPO levels in groups A and B (Figure 1). In gro u p
B, days 3, 6, 9, and 12 trough levels in the 1.2 and 2.4
µg/kg dose groups were similar and increased >1 0 - f o l d
over baseline values. The peak levels of serum TPO
achieved were greatest in the 2.4 µg/kg dose group and
i n c reased >50-fold over baseline values. 
TPO-Specific Antibody Assessment After Therapy
No neutralizing TPO-specific antibodies were observed.
One subject had antibodies specific to the full-length TPO
molecule detected in the screening ELISA before receiving
rhTPO. This patient did not have an increase in antibody
titer after receiving rhTPO and there were no clinical
sequelae.
DISCUSSION
The reasons for prolonged thrombocytopenia after
transplantation are multifactorial, and it is likely that the
Table 4. Bleeding Events During the Study Period*
Event Number of Patients
Ecchymoses/hematoma 7
Gastrointestinal bleeding 5
Requiring RBC transfusion 1
Hematuria 4
Epistaxis 3
Vaginal bleeding 2
*RBC indicates red blood cell.
Table 5. Platelet Recovery by rhTPO Dose Group During the Study Period
Group A Dose ( µg/kg) Group B Dose ( µg/kg)
0.6 1.2 2.4 0.6 1.2 2.4 Total
Recovery of platelet counts (n) 8 6 5 7 6 6 38
≥20,000/ µL 2 1 2 2 2 1 10
50,000/ µL 0 0 2 0 0 0 2
Increase in megakaryocyte content of marrow
Evaluable marrow studies (n) 6 5 4 6 4 5 30
Megakaryocyte increase associated with platelet recovery 0 0 1 1 1 0 3
30
same mechanisms contribute to both primary and sec-
o n d a ry failures (platelet counts initially re c o v e r, but then
later decrease). Thrombocytopenia may occur after trans-
plantation because platelet production from the marrow is
reduced as a result of poor engraftment or the presence of
i n h i b i t o ry factors [33-37]. All but 3 patients in this study
had hypocellular marrows and all patients had decre a s e d
numbers of marrow megakaryocytes at study entry, con-
f i rming a deficit in the capacity for platelet pro d u c t i o n .
Tr a n s p l a n t - related complications including infections,
VOD of the liver, autoimmune/alloimmune thro m b o c y-
topenia, GVHD, and hemolytic-uremic syndrome may also
contribute to low platelet counts because of increased con-
sumption [2,4,38-44]. In the presence of a deficit in the
capacity for platelet production, disorders that cause even
low-grade platelet consumption may result in severe
t h rombocytopenia. Platelet survival was not assessed in this
s t u d y, so it is unknown to what extent increased consump-
tion contributed to the severity of the thro m b o c y t o p e n i a .
The 3 patients with baseline marrow cellularity >70% may
have had a significant component of increased consumption
that contributed to the development of severe thro m b o c y-
topenia. Even so, if the platelet production from the mar-
row was to some degree inadequate, stimulation of
m e g a k a ryocytopoiesis with thrombopoietin might be
expected to increase platelet counts [45].
P reclinical studies in mice were the first to show that
the administration of rhTPO or megakaryocyte gro w t h
and diff e rentiation factor (MGDF) (a 163-amino acid
sequence identical to the N-terminal portion of the native
t h rombopoietin) after (1) nonmyeloablative chemotherapy
or total-body irradiation (TBI) or (2) myeloablation and
transplantation could reduce both the time to re c o v e ry and
the nadir of the platelet counts [18-22,46]. Recovery of
platelet counts after sublethal TBI (500 cGy) or single-
dose chemotherapy in nonhuman primates was accelerated
with the administration of rhTPO or MGDF
[23,26,47,48]. Treatment with rhTPO and MGDF also
stimulated the re c o v e ry of other lineages, including re d
blood cells and neutrophils [49-51]. Thrombopoietin was
less effective in this model than in other models for
d e c reasing the time to platelet re c o v e ry after marrow or
blood stem cell transplantation in nonhuman primates or
dogs, although early administration of high-dose TPO
may be more effective (R.A.N., unpublished observ a t i o n s )
[ 5 2 - 5 4 ] .
The first human studies of rhTPO were carried out
with cancer patients who were scheduled to re c e i v e
c h e m o t h e r a p y. To evaluate its effects on otherwise intact
m a rro w, rhTPO was administered before chemotherapy.
Platelet counts increased 61% to 213% over baseline
and the rhTPO half-life in the serum was 20-30 hours
[27]. After chemotherapy, rhTPO and pegylated-MGDF
stimulated re c o v e ry to baseline platelet counts more
rapidly than placebo or historical controls [29,30,55].
Some of the chemotherapy regimens used in these stud-
ies  did not  induce severe thrombocytopenia  in  the
placebo controls. MGDF reduces the duration of severe
t h rombocytopenia and the need for platelet transfusions
after autologous marrow transplantation but is less eff e c-
tive after blood stem cell transplantation [56,57]. This
study is the first re p o rt of the treatment with rhTPO of a
m a rrow failure syndrome associated with pro l o n g e d
s e v e re t h ro m b o c y t o p e n i a .
The administration of rhTPO to patients in other set-
tings has generally been well tolerated. Adverse eff e c t s
o b s e rved in this study were primarily considered trans-
p l a n t - related rather than associated with rhTPO. A small
number of thrombotic events have been described in other
clinical studies, but it remains unclear if there is an associa-
tion with rhTPO [29,30]. Antibodies to rhTPO did not
develop in this study, although a non-neutralizing antibody
that bound TPO was identified in the serum of 1 patient
b e f o re the start of treatment with rhTPO. In pre c l i n i c a l
studies, the development of neutralizing antibodies to
rhTPO was associated with a transient decrease of platelet
counts which persisted for weeks to months [58,59]. In
these preclinical studies, platelet survival was unchanged,
indicating that the decreased platelet counts were sec-
o n d a ry to decreased production. The use of rhTPO in
other species may increase the risk for the development of
neutralizing antibodies. In more than 400 subjects tre a t e d
in clinical studies of rhTPO, no subject has developed neu-
tralizing antibodies (Genentech, data on file).
T h e re was no apparent dose-response effect noted on
platelet counts or marrow megakaryocyte content, although
Table 6. Transfusion Events During the Study Period
Median Number of Platelet Median Numberof Red Blood Cell
Dose Group Number of Transfusion Events/Patient Transfusion Events/Patient
(mg/kg) Patients (Range) (Range)
Group A
0.6 8 9 (2-20) 3 (0-11) 
1.2 6 3 (1-16) 1 (0-8) 
2.4 5 7 (2-12) 4 (2-5) 
Group B
0.6 7 9 (1-14) 2 (2-5) 
1.2 6 8 (0-13) 3 (2-5) 
2.4 6 4 (0-13) 3 (0-8)
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Figure 1. Serum TPO levels. rhTPO was administered at doses of 0.6 mg/kg, 1.2 mg/kg, and 2.4 µg/kg as a single dose (Group A) or in multiple doses every 3
days for a total of 5 doses (Group B). Baseline (B), peak (P) and trough (T) mean serum TPO levels were obtained for both Groups A and B. Baseline serum TPO
levels were measured just before administration of rhTPO dose. Peak serum TPO levels were obtained 10 minutes after the bolus infusion of the rhTPO dose. In
Group A, all trough levels were done at 24 hours after treatment. In Group B, trough levels were obtained immediately before the next dose (at 72 hours) except
for the serum TPO level on day 13, which was 24 hours after the last dose. Shown are the mean ± standard deviation values for each dose.
32
this study was not designed to evaluate such a re s p o n s e .
The dose range that was selected had previously been
demonstrated to be biologically active [27,28]. Scheduling
of doses in group B was based on the prolonged half-life of
rhTPO as a result of the decreased platelet count in the
blood and megakaryocyte mass in the marro w. TPO levels
achieved were dose-related and sustained for up to 3 days,
significantly above the already elevated baseline levels at
study entry. The significance of serum TPO levels in re l a-
tion to clinical response is uncertain. However, it was ascer-
tained that the doses studied with a 3-day dosing schedule
w e re safe and sufficient to maintain substantially incre a s e d
t rough serum levels of TPO. In normal mice, 50% of all c-
mpl receptors were saturated with rhTPO at a dose of 6.4
µg/kg [60]. The dosing of rhTPO re q u i red to saturate c-
mpl in humans who are thrombocytopenic has not been
re p o rted. The number of responses in the lower dose
g roups was similar to that observed in the higher dose
g roups. In patients who re c o v e red platelet counts during
the 28-day study period, the start of re c o v e ry was usually
o b s e rved after 14 days of rhTPO treatment. Because spon-
taneous re c o v e ry of platelet counts would be expected in
some patients, it is uncertain in the absence of a dose-
response relationship whether responses occurred due to
the rh T P O .
In summary, rhTPO could be administered safely to
patients with severe prolonged thrombocytopenia after
H S C T. At the rhTPO doses and schedules studied, no
d o s e - response relationship was observed among those
patients who re c o v e red platelet counts during the 28-day
study period. Further studies to evaluate rhTPO dosing
and schedules or a combinat ion of cel l therapy and
cytokines are re q u i red in patients with delayed platelet
re c o v e ry.
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